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 Calcineurin inhibitor nephrotoxicity is 
one of the leading causes of chronic allo-
graft dysfunction. 1 – 3 Unfortunately, 
increased serum creatinine lags well 
behind the appearance of signifi cant his-
tologic damage to the kidney seen, in part, 
as hyalinosis. Th is hyalinosis is focal and 
beaded in appearance as opposed to the 
circumferential hyalinosis produced by 
diabetes or hypertension. Because of the 
focal nature, histologic examination of 
serial sections from two diff erent biopsy 
cores is recommended for accurate iden-
tifi cation and diagnosis. Th e molecular 
and cellular mechanisms contributing to 
the overall pathologic process of hyalino-
sis are the subject of the study by Chiasson 
 et al. 4 (this issue). 
 Th e macrolid lactone tacrolimus (also 
known as FK-506) is an immunosuppres-
sant that decreases the risk of organ rejec-
tion by binding to the immunophilin 
FK-506 – binding protein-12 (FKBP12). 
Chiasson and co-workers hypothesized 
that in addition to its known effect of 
increasing transforming growth factor-  
(TGF-  ) levels, tacrolimus relieves a tonic 
inhibition of TGF-  signaling as it inter-
acts with FKBP12, ultimately boosting 
activation of the transcription cofactors 
Smad2 and Smad3 and extracellular 
matrix protein production, thus causing 
smooth muscle injury and eventual hyali-
nosis. 4 In order to mechanistically dissect 
the process and determine the contribu-
tion of endothelial cells, the authors devel-
oped endothelial-specific FKBP12 
knockout mice by crossing mice contain-
ing loxP sites fl anking either side of the 
FKBP12 gene with mice expressing Cre 
driven by the endothelial-specifi c Tie2 
promoter. Th ese mice were found to be 
defi cient in FKBP12 in isolated endothe-
lial cells and did not have elevated levels 
of angiotensin II (a driver of TGF-  pro-
duction in renal diseases) or TGF-  in 
their serum or increased TGF-  mRNA 
expression in isolated aortas. In this study 
it was assumed that aortas refl ect the bio-
logy of renal arterioles. Wild-type mice, 
treated with 10  mg / kg / d tacrolimus for 
1 week, exhibited histologic evidence of 
arteriolar hyalinosis in kidney sections. 
Similar hyalinosis was seen in the kidneys 
of untreated 12 – week-old endothelial-
specifi c FKBP12 knockout mice. In the 
aortas of the wild-type mice there was 
activation (phosphorylation) of the TGF-
  -linked transcription factors Smad2 and 
Smad3, and increased production of the 
extracellular matrix proteins collagen I 
and fi bronectin. All these eff ects were also 
seen in the aortas of the untreated 
endothelial-specifi c FKBP12 knockout 
mice. In aortas isolated from wild-type 
mice, treatment with tacrolimus caused 
Smad2 / 3 activation and increased expres-
sion of collagen I and fi bronectin, eff ects 
inhibited  in vitro by prior endothelial-cell 
denudation of the aortas or inhibition of 
the TGF-  receptor by the small molecule 
SB-505124, thus confi rming the involve-
ment of endothelial cells and TGF-  
receptor signaling in events leading up to 
hyalinosis. Th e eff ect of tacrolimus  in vitro 
was not prevented by incubation with cal-
cineurin autoinhibitory peptide, further 
indicating the TGF-  pathway and not 
calcineurin inhibition as the mechanistic 
conduit leading to hyaline deposition. Th e 
authors do not know whether this same 
pathway is responsible for ciclosporin-
induced arteriolar hyalinosis. 
 Although the study strongly implicates 
indirect TGF-  type I receptor (TGF-  RI) 
activation as an initiating event in the 
overall biologic process of tacrolimus-
induced arteriolar hyalinosis, the authors 
rightly caution about the concentration of 
tacrolimus used in their studies both 
 in vivo and  in vitro . To achieve eff ects of 
tacrolimus in short order, doses many 
times higher than those seen clinically 
were used. Although there was successful 
knockout of FKBP12, the authors found 
expression of FKBP12.6. This is not 
unanticipated, as they are separate gene 
products, with FKBP12 located on mouse 
chromosome 2 (human chromosome 20) 
and FKBP12.6 located on mouse 
chromosome 12 (human chromosome 2). 
Although both FKBP12 and FKBP12.6 
regulate intracellular calcium levels 
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 Tacrolimus (FK-506) controls organ rejection; however, arteriolar 
hyalinosis is a frequent complication. By use of mice lacking FK-506-
binding protein-12 in endothelial cells, Chiasson and co-workers 
explored the contribution of endothelial cells and the transforming 
growth factor-  pathway to define mechanisms of hyalinosis. Absence 
of this binding protein removed a tonic inhibition to activate the 
transforming growth factor-  system, causing arteriolar hyalinosis. 
However, tacrolimus can have effects on any biologic process involving 
receptors with a GS domain. 
 Kidney International (2012)  82, 838 – 839.  doi: 10.1038/ki.2012.178 
 1 Division of Clinical and Translational Research, 
Department of Anesthesiology, School of Medicine, 
Washington University in St Louis ,  St Louis ,  Missouri , 
 USA and  2 Siteman Cancer Center, School of Medicine, 
University in St Louis ,  St Louis ,  Missouri ,  USA 
 Correspondence: Jeremiah J. Morrissey, 
Division of Clinical and Translational Research, 
Department of Anesthesiology, School of 
Medicine, Washington University in St Louis, 
Campus Box 8054, Siteman Cancer Center, 
660 S. Euclid Avenue, St Louis, Missouri 63110, USA. 
E-mail:  morrisse@wustl.edu 
see original article on page 857
commentar y
Kidney International (2012) 82     839
through ryanodine and inositol-1,4,5-tri-
phosphate receptors, FKBP12.6 does not 
seem to interact with type I receptors of 
the TGF-  family. 5 – 7 As was mentioned 
before, a major consideration is the 
assumption that isolated aortas refl ect the 
biology of renal arterioles, and this needs 
more rigorous investigation. 
 Th ere are other considerations to be 
gleaned from this study. Of importance 
to this study is that in the absence 
of ligands such as tacrolimus, FKBP12 
also interacts with the intracellular 
glycine / serine-rich domain (GS motif) of 
TGF-  RI, stabilizing it in an inactive 
conformation 6,7 ( Figure 1 ). Th is stabiliza-
tion of TGF-  RI prevents spontaneous 
interaction with the type II receptor 
(TGF-  RII), even in the absence of 
TGF-  , thus preventing low-level activa-
tion of the signaling system by phospho-
rylation of the transcription factors Smad2 
and Smad3. In essence, FKBP12 prevents 
leakiness of the TGF-  signaling system. 6,7 
Both activin-like kinase-I (another type I 
receptor that interacts with TGF-  RII 
in endothelial cells) and TGF-  RI, and 
presumably all type I receptors with a 
GS motif, interact with FKBP12, thereby 
preventing a leakiness in receptor activa-
tion and subsequent biologic responses. 6,7 
Chiasson  et al. 4 are correct that  ‘ future 
immunosuppressive drugs that do not 
increase TGF-  levels or lead to TGF-  
receptor activation ’ need to be developed 
to eliminate or minimize arteriolar hyali-
nosis. Th ese future drugs need to be TGF-
  type I-specifi c to eliminate unintended 
side eff ects involving other type I recep-
tors of the extended TGF-  superfamily 
that may be coupled to benefi cial homeo-
static pathways. 
 Traditionally, hyalinosis is thought to 
result from excessive extracellular matrix 
production by smooth muscle cells; now 
Chiasson and co-workers implicate 
endothelial cells as well 4 ( Figure 1 ). Addi-
tionally, leakage of plasma proteins across 
the damaged endothelia is thought to con-
tribute to the protein buildup character-
ized as homogeneous pink-staining 
material ( Figure 1 ). Th is reduces the fl exi-
bility of the renal arterioles and decreases 
renal function. Thus, direct (through 
ligand) or indirect (through macrolid) 
endothelial-cell TGF-  RI activation is suf-
fi cient to initiate arteriolar hyalinosis. 
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 Figure 1  |  Direct or indirect activation of the TGF-  type I receptor by TGF-  or tacrolimus, 
respectively, leads to arteriolar hyalinosis. Receptor activation leads to activation of the 
transcription factors Smad2 and Smad3 and increased synthesis of the extracellular matrix proteins 
collagen I and fibronectin by endothelial cells. This, in turn, induces smooth muscle cell injury 
and eventual hyaline deposition. Another contributor to the hyaline deposits are plasma proteins 
leaked across damaged endothelium. FKBP12, FK-506-binding protein-12; TGF-  RI, TGF-  type I 
receptor. 
